Whilst it may not be a huge deal, we thought it was good to see that the Tango Therapeutics, Inc. (NASDAQ:TNGX) Independent Director, Mace Rothenberg, recently bought US$74k worth of stock, for US$3.70 per share. Even though that isn't a massive buy, it did increase their holding by 400%, which is arguably a good sign.
The Last 12 Months Of Insider Transactions At Tango Therapeutics
Over the last year, we can see that the biggest insider sale was by the President, Barbara Weber, for US$115k worth of shares, at about US$12.62 per share. While we don't usually like to see insider selling, it's more concerning if the sales take place at a lower price. It's of some comfort that this sale was conducted at a price well above the current share price, which is US$4.08. So it may not tell us anything about how insiders feel about the current share price.
Over the last year we saw more insider selling of Tango Therapeutics shares, than buying. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!
For those who like to find hidden gems this free list of small cap companies with recent insider purchasing, could be just the ticket.
Insider Ownership
For a common shareholder, it is worth checking how many shares are held by company insiders. I reckon it's a good sign if insiders own a significant number of shares in the company. Our data indicates that Tango Therapeutics insiders own about US$7.3m worth of shares (which is 1.8% of the company). However, it's possible that insiders might have an indirect interest through a more complex structure. We do generally prefer see higher levels of insider ownership.
So What Does This Data Suggest About Tango Therapeutics Insiders?
The recent insider purchase is heartening. But we can't say the same for the transactions over the last 12 months. We're not thrilled with the relatively low insider ownership and the longer term transaction history. But we like the recent purchasing. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Tango Therapeutics. Case in point: We've spotted 4 warning signs for Tango Therapeutics you should be aware of, and 2 of them are significant.
If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
